Table of contents
- Trial overview
- Who was studied
- What the trial measured
- Trial phase and size
- Treatments in the study
- What this means for patients
Trial overview
The main trial in the source data was DANHEART, a completed Phase 3 study in people with heart failure.[1] It studied Hydralazine Hydrochloride as part of a Hydralazine/isosorbide dinitrate treatment group and also included a separate metformin comparison.[1]
Who was studied
The trial focused on patients with chronic heart failure and reduced left ventricular ejection fraction of 40% or less.[1] The brief summary says these patients were already on optimal treatment, which means they were receiving the best standard care used in the study setting.[1]
What the trial measured
The main outcome for the Hydralazine/isosorbide dinitrate part of the trial was a combined measure of serious heart failure events.[1] These events included death, hospitalization with worsening heart failure, urgent visits that needed intravenous therapy or metolazone therapy, heart transplantation, or implantation of a left ventricular assist device (LVAD).[1]
The metformin part of the study used a broader combined outcome that also included acute myocardial infarction and stroke.[1] A composite endpoint means the study counts several important outcomes together instead of looking at only one event.[1]
Trial phase and size
DANHEART was a large Phase 3 trial with an enrollment of 1,500 people.[1] Phase 3 studies are usually done to see whether a treatment helps a meaningful number of patients and to collect more information in a larger group.[1]
Treatments in the study
The intervention list included BiDil, placebo for Hydralazine/isosorbide dinitrate, placebo for metformin hydrochloride, and metformin hydrochloride.[1] In the source data, Hydralazine Hydrochloride appears in the Hydralazine/isosorbide dinitrate treatment group rather than as a stand-alone study drug.[1]
- BiDil was given orally in the study.[1]
- Placebo means an inactive look-alike treatment used for comparison.[1]
- Metformin hydrochloride was also studied in the same trial, showing that DANHEART compared more than one approach.[1]
What this means for patients
Based on the source data, the research on Hydralazine Hydrochloride is centered on serious outcomes in heart failure, not on short-term symptoms alone.[1] The trial population was specific: adults with chronic heart failure, reduced pumping function of the heart, and ongoing standard treatment.[1] Because the study is completed, the data are meant to help researchers understand whether the treatment strategy lowered major heart failure events in this group.[1]
